الفهرس 
cover EnglishOnly 14 pages are availabe for public view
 |  | from | 185 |  |  |
| | | from | 185 | | |
Abstract
The aim of this work is to study the expression of complement regulatory molecules: CD35, CD55, CD59, and CD46 in adult acute leukemia, determine the level of expression compared to normal control, correlate the level of expression to other laboratory and clinical parameters with emphasis on findings with prognostic relevance, and correlate the findings to remission induction. To achieve this aim, this study was performed on 65 adult AML patients presented to the clinic of NCI. Twenty age and sex matched apparently healthy individuals were included as a control group. Samples were analyzed by flow cytometry. This study documented that CD35, CD55, CD46 and CD59 are expressed on all AML blasts in a higher percentage than controls. This is one of the ways the leukaemic cells protect themselves from the lytic effect of the complement. CD35 and, to some extent, CD55 might have a relation to survival rate. CD59 was the only one which showed a relation to the remission rate. Key words: Acute myeloid leukaemia, Complement regulatory proteins, CD35, CD55, CD59, and CD46.